Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nano-X Imaging (NNOX) Asset Writedowns and Impairment (2021 - 2024)

Nano-X Imaging posted quarterly Asset Writedowns and Impairment of $86000.0 for Q4 2024, down 98.78% year-on-year from $7.1 million in Q1 2024, and up 256.36% on a QoQ basis from -$55000.0 in Q3 2024.

Nano-X Imaging (NNOX) has 4 years of Asset Writedowns and Impairment data on file, last reported at $86000.0 in Q4 2024.

  • For the quarter ending Q4 2024, Asset Writedowns and Impairment fell 98.78% year-over-year to $86000.0; the trailing twelve-month figure through Dec 2024 stood at $202000.0 (down 97.46% YoY), and the FY2025 full-year result was $17.5 million, up 8577.23% from the prior year.
  • Asset Writedowns and Impairment for Q4 2024 stood at $86000.0, up from -$55000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $36.5 million in Q4 2022 and bottomed at -$55000.0 in Q3 2024.
  • The 4-year median for Asset Writedowns and Impairment is $145000.0 (2023), against an average of $5.4 million.
  • The widest annual swing landed in 2022, when Asset Writedowns and Impairment jumped 91250.0%; it then sank 107.45% in 2024.
  • A 4-year view of Asset Writedowns and Impairment shows it stood at $40000.0 in 2021, then surged by 91250.0% to $36.5 million in 2022, then tumbled by 80.69% to $7.1 million in 2023, then slumped by 98.78% to $86000.0 in 2024.
  • The last three Asset Writedowns and Impairment figures came in at $86000.0 (Q4 2024), -$55000.0 (Q3 2024), and $146000.0 (Q2 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Nano-X Imaging 126,664.45 -59.48 Mn -3.62 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2024 86,000.00
Dec 31, 2024 86,000.00
Sep 30, 2024 -55,000.00
Sep 30, 2024 -55,000.00
Jun 30, 2024 146,000.00
Jun 30, 2024 146,000.00
Mar 31, 2024 25,000.00
Mar 31, 2024 25,000.00
Dec 31, 2023 7.06 Mn
Dec 31, 2023 7.06 Mn
Sep 30, 2023 738,000.00
Sep 30, 2023 738,000.00
Mar 31, 2023 145,000.00
Mar 31, 2023 145,000.00
Dec 31, 2022 36.54 Mn
Dec 31, 2022 36.54 Mn
Jun 30, 2022 14.34 Mn
Jun 30, 2022 14.34 Mn
Mar 31, 2022 28,000.00
Mar 31, 2022 28,000.00
Dec 31, 2021 40,000.00
Dec 31, 2021 40,000.00